- « Previous
- Clinical Pharmacology
- Next »
Priftin
Clinical Pharmacology
Priftin
Patient Weight
<50 kg
≥ 50 kg
600
600
300
300
1500
2000
800
1200
Continuation Phase
Rifapentine (mg)
Isoniazid (mg)
Once Weekly
Once Weekly
Patient Weight
<50 kg
≥ 50 kg
600
600
600
900
Rifapentine Combination Treatment
Intensive Phase
Rifapentine (mg)
Isoniazid (mg)
Pyrazinamide (mg)
Ethambutol (mg)
Daily
Daily
Daily
Daily
Patient Weight
<50 kg
≥ 50 kg
450
600
300
300
1500
2000
800
1200
Continuation Phase
Rifapentine (mg)
Isoniazid (mg)
Twice Weekly
Twice Weekly
Patient Weight
<50 kg
≥ 50 kg
450
600
600
900
* Ethambutol was to be discontinued once baseline susceptiblity test results were available.
Priftin Proposed Text of the Labeling (Annotated)
Table 2-2 presents clinical outcome in study 008.
| Table 2-2 presents clinical outcome in study 008. | ||
|
Rifapentine Combination |
Rifapentine Combination | |
|
Status at End of Treatment: | ||
| Converted |
67% (249/286) |
81% (229/284) |
| Not Converted |
1% (4/286) |
3% (8/284) |
| Lost to Follow-up |
12% (33/286) |
17% (47/284) |
| Status in follow up. | ||
| Relapsed |
Brand Name: Priftin
Generic Name: Rifapentine
Bookmark this page:
WebMD DailyGet breaking medical news. PriftinHealth Resources
Drug NewsRxList HomeDrugs & Medications A-Z List Pill Identification Tool Drug Medical Dictionary Diseases & Conditions
About RxListContact RxListTerms & ConditionsPrivacy PolicySponsor PolicySite Map WebMD®MedScape®eMedicineHealth®MedicineNet® Copyright © 2008 by RxList Inc.
 RxList does not provide medical advice, diagnosis or treatment. See additional information. | |
2008 Election & Health Care on WebMD. Get Informed.
Updated & New